人肝癌组织肿瘤浸润淋巴细胞穿孔素、Fas配体表达的研究

Perforin and Fas ligand expression of tumor infiltrating lymphocytes in human hepatocellular carcinoma

目的研究肝癌组织肿瘤浸润淋巴细胞（ＴＩＬ）的穿孔素及Ｆａｓ配体（ＦａｓＬ）表达情况。方法应用原位杂交及免疫组化ＡＢＣ方法检测２０例病人原发性肝细胞癌组织的ＴＩＬ中穿孔素及ＦａｓＬ的ｍＲＮＡ及其蛋白的表达情况。结果２０例肝癌病人中１６例（占８０％）肝癌组织中ＴＩＬ表达穿孔素及ＦａｓＬ，其中１例病人的绝大多数ＴＩＬ表达穿孔素及ＦａｓＬ，该例病人手术后１年６个月仍未复发，除该例以外，其余１５例肝癌组织中ＴＩＬ的穿孔素及ＦａｓＬ表达率＜１０％。结论绝大多数肝癌组织中存在着具有杀伤活性的ＴＩＬ细胞，然而，这种具有杀伤活性ＴＩＬ细胞仅占总ＴＩＬ细胞的极少一部分，需要体内或体外进一步扩增。

Objective To investigate perforin and Fas ligand (Fas L) expression of tumor infiltrating lymphocytes (TIL) in human hepatocellular carcinoma (HCC). Methods Expression of perforin and Fas L of TIL was studied in 20 HCC cases using in situ hybridization and immunohistochemistry. Results Expression of perforin and Fas L gene were detected in TIL in 80% of the cases studied. Among them, one patient (no. 14) in whom expression of perforin and Fas L were noticed in the majority of the TIL, had no recurrence of HCC for one and one half (1.5) year after tumor resection. It indicates that presence of large number of activated T cells might be beneficial for the tumor therapy. In the remaining cases, only 10% of TIL were obtained able to express perforin and Fas L indicating that only a few TIL were activated and cytotoxic to HCC. Conclusions Even there were a multitude of T cells infiltrating in HCC, only few of them were immunoactived and to be cytotoxic to HCC. It seems important to adopt measures in order to promote further proliferation of these activated T cells either in vitro or in vivo.